Skip to main content

Advertisement

SpringerLink
Log in

New definition of metabolic dysfunction-associated fatty liver disease with elevated brachial-ankle pulse wave velocity and albuminuria: a prospective cohort study

  • Research Article
  • Published:
Frontiers of Medicine Aims and scope Submit manuscript

Abstract

A new definition of metabolic dysfunction-associated fatty liver disease (MAFLD) has recently been proposed. We aim to examine the associations of MAFLD, particularly its discordance from non-alcoholic fatty liver disease (NAFLD), with the progression of elevated brachial-ankle pulse wave velocity (baPWV) and albuminuria in a community-based study sample in Shanghai, China. After 4.3 years of follow-up, 778 participants developed elevated baPWV and 499 developed albuminuria. In comparison with the non-MAFLD group, the multivariable adjusted odds ratio (OR) of MAFLD group for new-onset elevated baPWV was 1.25 (95% confidence interval (CI) 1.01–1.55) and 1.35 (95% CI 1.07–1.70) for albuminuria. Participants without NAFLD but diagnosed according to MAFLD definition were associated with higher risk of incident albuminuria (OR 1.77; 95% CI 1.07–2.94). Patients with MAFLD with high value of hepamet fibrosis score or poor-controlled diabetes had higher risk of elevated baPWV or albuminuria. In conclusion, MAFLD was associated with new-onset elevated baPWV and albuminuria independently of body mass index, waist circumference, and hip circumference. Individuals without NAFLD but diagnosed as MAFLD had high risk of albuminuria, supporting that MAFLD criteria would be practical for the evaluation of long-term risk of subclinical atherosclerosis among fatty liver patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology 2020; 158(7): 1999–2014.e1

    Article  CAS  PubMed  Google Scholar 

  2. Eslam M, Sarin SK, Wong VW, Fan JG, Kawaguchi T, Ahn SH, Zheng MH, Shiha G, Yilmaz Y, Gani R, Alam S, Dan YY, Kao JH, Hamid S, Cua IH, Chan WK, Payawal D, Tan SS, Tanwandee T, Adams LA, Kumar M, Omata M, George J. The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease. Hepatol Int 2020; 14(5): 889–919

    Article  PubMed  Google Scholar 

  3. Mendez-Sanchez N, Arrese M, Gadano A, Oliveira CP, Fassio E, Arab JP, Chávez-Tapia NC, Dirchwolf M, Torre A, Ridruejo E, Pinchemel-Cotrim H, Castellanos Fernández MI, Uribe M, Girala M, Diaz-Ferrer J, Restrepo JC, Padilla-Machaca M, Dagher L, Gatica M, Olaechea B, Pessôa MG, Silva M. The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease. Lancet Gastroenterol Hepatol 2021; 6(1): 65–72

    Article  PubMed  Google Scholar 

  4. Shiha G, Alswat K, Al Khatry M, Sharara AI, Örmeci N, Waked I, Benazzouz M, Al-Ali F, Hamed AE, Hamoudi W, Attia D, Derbala M, Sharaf-Eldin M, Al-Busafi SA, Zaky S, Bamakhrama K, Ibrahim N, Ajlouni Y, Sabbah M, Salama M, Anushiravani A, Afredj N, Barakat S, Hashim A, Fouad Y, Soliman R. Nomenclature and definition of metabolic-associated fatty liver disease: a consensus from the Middle East and north Africa. Lancet Gastroenterol Hepatol 2021; 6(1): 57–64

    Article  PubMed  Google Scholar 

  5. Spearman CW, Desalegn H, Ocama P, Awuku YA, Ojo O, Elsahhar M, Abdo AA, Ndububa DA, Fouad Y, Borodo MM, Ng’wanasayi M, Ally R, Elwakil R. The sub-Saharan Africa position statement on the redefinition of fatty liver disease: from NAFLD to MAFLD. J Hepatol 2021; 74(5): 1256–1258

    Article  PubMed  Google Scholar 

  6. Fouad Y, Elwakil R, Elsahhar M, Said E, Bazeed S, Ali Gomaa A, Hashim A, Kamal E, Mehrez M, Attia D. The NAFLD-MAFLD debate: eminence vs evidence. Liver Int 2021; 41(2): 255–260

    Article  PubMed  Google Scholar 

  7. European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical Practice Guidelines for the management of nonalcoholic fatty liver disease. J Hepatol 2015; 54(5): 1388–1402

    Google Scholar 

  8. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, Zelber-Sagi S, Wai-Sun Wong V, Dufour JF, Schattenberg JM, Kawaguchi T, Arrese M, Valenti L, Shiha G, Tiribelli C, Yki-Järvinen H, Fan JG, Grønbæk H, Yilmaz Y, Cortez-Pinto H, Oliveira CP, Bedossa P, Adams LA, Zheng MH, Fouad Y, Chan WK, Mendez-Sanchez N, Ahn SH, Castera L, Bugianesi E, Ratziu V, George J. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol 2020; 73(1): 202–209

    Article  PubMed  Google Scholar 

  9. Rinella ME. Nonalcoholic fatty liver disease: a systematic review. JAMA 2015; 313(22): 2263–2273

    Article  CAS  PubMed  Google Scholar 

  10. Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Nonalcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol 2015; 65(3): 589–600

    Article  Google Scholar 

  11. Ohkuma T, Ninomiya T, Tomiyama H, Kario K, Hoshide S, Kita Y, Inoguchi T, Maeda Y, Kohara K, Tabara Y, Nakamura M, Ohkubo T, Watada H, Munakata M, Ohishi M, Ito N, Nakamura M, Shoji T, Vlachopoulos C, Yamashina A, Nagano M, Yukiyo O, Kabutoya T, Asayama K, Takashima N, Chowdhury TT, Mitsuki-Shinohara K, Yamashita T; Collaborative Group for J-BAVEL (Japan Brachial-Ankle Pulse Wave Velocity Individual Participant Data Meta-Analysis of Prospective Studies). Brachial-ankle pulse wave velocity and the risk prediction of cardiovascular disease: an individual participant data meta-analysis. Hypertension 2017; 69(6): 1045–1052

    Article  CAS  PubMed  Google Scholar 

  12. Matsushita K, Coresh J, Sang Y, Chalmers J, Fox C, Guallar E, Jafar T, Jassal SK, Landman GW, Muntner P, Roderick P, Sairenchi T, Schöttker B, Shankar A, Shlipak M, Tonelli M, Townend J, van Zuilen A, Yamagishi K, Yamashita K, Gansevoort R, Sarnak M, Warnock DG, Woodward M, Ärnlöv J; CKD Prognosis Consortium. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015; 3(7): 514–525

    Article  PubMed  PubMed Central  Google Scholar 

  13. Zheng J, Zhou Y, Zhang K, Qi Y, An S, Wang S, Zhao X, Tang YD. Association between nonalcoholic fatty liver disease and subclinical atherosclerosis: a cross-sectional study on population over 40 years old. BMC Cardiovasc Disord 2018; 18(1): 147

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Zhu WH, Fang LZ, Lu CR, Dai HL, Chen JH, Qiao QH, Chen LY. Correlation between non-alcoholic fatty liver with metabolic risk factors and brachial-ankle pulse wave velocity. World J Gastroenterol 2015; 21(35): 10192–10199

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Li N, Zhang GW, Zhang JR, Jin D, Li Y, Liu T, Wang RT. Nonalcoholic fatty liver disease is associated with progression of arterial stiffness. Nutr Metab Cardiovasc Dis 2015; 25(2): 218–223

    Article  CAS  PubMed  Google Scholar 

  16. Kang SH, Cho KH, Do JY. Non-alcoholic fatty liver disease is associated with low-grade albuminuria in men without diabetes mellitus. Int J Med Sci 2019; 15(2): 285–291

    Article  Google Scholar 

  17. Li M, Xu Y, Xu M, Ma L, Wang T, Liu Y, Dai M, Chen Y, Lu J, Liu J, Bi Y, Ning G. Association between nonalcoholic fatty liver disease (NAFLD) and osteoporotic fracture in middle-aged and elderly Chinese. J Clin Endocrinol Metab 2012; 97(5): 2033–2038

    Article  CAS  PubMed  Google Scholar 

  18. Xin Z, Zhu Y, Wang S, Liu S, Xu M, Wang T, Lu J, Chen Y, Zhao Z, Wang W, Ning G, Bi Y, Xu Y, Li M. Associations of subclinical atherosclerosis with nonalcoholic fatty liver disease and fibrosis assessed by non-invasive score. Liver Int 2020; 40(4): 806–814

    Article  PubMed  Google Scholar 

  19. Ampuero J, Pais R, Aller R, Gallego-Durán R, Crespo J, García-Monzón C, Boursier J, Vilar E, Petta S, Zheng MH, Escudero D, Calleja JL, Aspichueta P, Diago M, Rosales JM, Caballería J, Gómez-Camarero J, Lo Iacono O, Benlloch S, Albillos A, Turnes J, Banales JM, Ratziu V, Romero-Gómez M; HEPAmet Registry. Development and validation of hepamet fibrosis scoring system—a simple, noninvasive test to identify patients with nonalcoholic fatty liver disease with advanced fibrosis. Clin Gastroenterol Hepatol 2020; 18(1): 216–225.e5

    Article  PubMed  Google Scholar 

  20. Stefan N. Causes, consequences, and treatment of metabolically unhealthy fat distribution. Lancet Diabetes Endocrinol 2020; 8(7): 616–627

    Article  PubMed  Google Scholar 

  21. Kim NH, Park J, Kim SH, Kim YH, Kim DH, Cho GY, Baik I, Lim HE, Kim EJ, Na JO, Lee JB, Lee SK, Shin C. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 2014; 100(12): 938–943

    Article  CAS  PubMed  Google Scholar 

  22. Hong HC, Hwang SY, Ryu JY, Yoo HJ, Seo JA, Kim SG, Kim NH, Baik SH, Choi DS, Choi KM. The synergistic impact of nonalcoholic fatty liver disease and metabolic syndrome on subclinical atherosclerosis. Clin Endocrinol (Oxf) 2015; 84(2): 203–209

    Article  Google Scholar 

  23. Wijarnpreecha K, Thongprayoon C, Boonpheng B, Panjawatanan P, Sharma K, Ungprasert P, Pungpapong S, Cheungpasitporn W. Nonalcoholic fatty liver disease and albuminuria: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2018; 30(9): 986–994

    Article  PubMed  Google Scholar 

  24. Liu Z, Suo C, Shi O, Lin C, Zhao R, Yuan H, Jin L, Zhang T, Chen X. The health impact of MAFLD, a novel disease cluster of NAFLD, is amplified by the integrated effect of fatty liver disease-related genetic variants. Clin Gastroenterol Hepatol 2020: S1542–3555(20)31729–8

    Google Scholar 

  25. Lin S, Huang J, Wang M, Kumar R, Liu Y, Liu S, Wu Y, Wang X, Zhu Y. Comparison of MAFLD and NAFLD diagnostic criteria in real world. Liver Int 2020; 40(9): 2082–2089

    Article  PubMed  Google Scholar 

  26. Lee H, Lee YH, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol 2020; S1542–3555(20): 31717–1

    Google Scholar 

  27. Stefan N, Häring HU, Cusi K. Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies. Lancet Diabetes Endocrinol 2019; 7(4): 313–324

    Article  PubMed  Google Scholar 

  28. Chen Y, Xu M, Wang T, Sun J, Sun W, Xu B, Huang X, Xu Y, Lu J, Li X, Wang W, Bi Y, Ning G. Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease. Atherosclerosis 2015; 241(1): 145–150

    Article  CAS  PubMed  Google Scholar 

  29. Yamamura S, Eslam M, Kawaguchi T, Tsutsumi T, Nakano D, Yoshinaga S, Takahashi H, Anzai K, George J, Torimura T. MAFLD identifies patients with significant hepatic fibrosis better than NAFLD. Liver Int 2020; 40(12): 3018–3030

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The investigators are grateful to all participants for their cooperation in the study. This work was supported by the grants from the National Key R&D Program of China (Nos. 2017YFC1310700, 2018YFC1311800, and 2018YFC1311705), the National Natural Science Foundation of China (Nos. 81870560, 82070880, 81941017, 81770842, 81970706, and 82022011), the National Science and Technology Major Project for “Significant New Drugs Development” (No. 2017ZX09304007), Shanghai Municipal Government (No. 18411951800), Shanghai Shenkang Hospital Development Center (Nos. SHDC12019101, SHDC2020CR1001A, and SHDC2020CR3059B), the Scientific and Technological Committee of Shanghai (No. 19411954200), Shanghai Jiao Tong University School of Medicine (No. DLY201801), Ruijin Hospital (No. 2018 CR002) and Shanghai Rising-Star Program (No. 21QA1408100).

Author information

Author notes

  1. The authors contributed equally to this work.

Authors and Affiliations

  1. Department of Endocrine and Metabolic Diseases, Shanghai Institute of Endocrine and Metabolic Diseases, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

    Jialu Wang, Shanshan Liu, Qiuyu Cao, Shujing Wu, Jingya Niu, Ruizhi Zheng, Lizhan Bie, Zhuojun Xin, Yuanyue Zhu, Shuangyuan Wang, Hong Lin, Tiange Wang, Min Xu, Jieli Lu, Yuhong Chen, Weiqing Wang, Guang Ning, Yu Xu, Mian Li, Yufang Bi & Zhiyun Zhao

  2. Shanghai National Clinical Research Center for Metabolic Diseases, Key Laboratory for Endocrine and Metabolic Diseases of the National Health Commission of the PR China, Shanghai Key Laboratory for Endocrine Tumor, State Key Laboratory of Medical Genomics, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

    Jialu Wang, Shanshan Liu, Qiuyu Cao, Shujing Wu, Jingya Niu, Ruizhi Zheng, Lizhan Bie, Zhuojun Xin, Yuanyue Zhu, Shuangyuan Wang, Hong Lin, Tiange Wang, Min Xu, Jieli Lu, Yuhong Chen, Weiqing Wang, Guang Ning, Yu Xu, Mian Li, Yufang Bi & Zhiyun Zhao

  3. Clinical Trials Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

    Yiping Xu

Authors
  1. Jialu Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shanshan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qiuyu Cao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Shujing Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jingya Niu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ruizhi Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lizhan Bie
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zhuojun Xin
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Yuanyue Zhu
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shuangyuan Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Hong Lin
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Tiange Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Min Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. Jieli Lu
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. Yuhong Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. Yiping Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. Weiqing Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. Guang Ning
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. Yu Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. Mian Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  21. Yufang Bi
    View author publications

    You can also search for this author in PubMed Google Scholar

  22. Zhiyun Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Mian Li, Yufang Bi or Zhiyun Zhao.

Ethics declarations

Jialu Wang, Shanshan Liu, Qiuyu Cao, Shujing Wu, Jingya Niu, Ruizhi Zheng, Lizhan Bie, Zhuojun Xin, Yuanyue Zhu, Shuangyuan Wang, Hong Lin, Tiange Wang, Min Xu, Jieli Lu, Yuhong Chen, Yiping Xu, Weiqing Wang, Guang Ning, Yu Xu, Mian Li, Yufang Bi, and Zhiyun Zhao have no conflict of interest to declare. All procedures followed were in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000 (5). Informed consent was obtained from all patients for being included in the study.

Supplementary materials

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wang, J., Liu, S., Cao, Q. et al. New definition of metabolic dysfunction-associated fatty liver disease with elevated brachial-ankle pulse wave velocity and albuminuria: a prospective cohort study. Front. Med. 16, 714–722 (2022). https://doi.org/10.1007/s11684-021-0888-8

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11684-021-0888-8

Keywords

Search

Navigation